Early Discharge With Injected Furosemide Versus Usual Care for Acute Heart Failure
Tests early hospital discharge with an injected diuretic in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure
Key facts
- Where
- Dallas, United StatesSee the 2 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07018297, who can take part
Where in United States
- Baylor Scott and White Health SystemDallas, United StatesNo longer taking part
- University of Texas Southwestern Medical CenterDallas, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Texas Southwestern Medical Center
- Trial code
- NCT07018297
- Record updated
- 5 November 2026
- Original description
This will be a prospective, cluster-randomized, crossover, non-inferiority trial of 250 participants within 48 hours of an inpatient admission for heart failure or emergency department presentation for heart failure with plans for admission or observation/short-stay hospitalization comparing early discharge using subcutaneous furosemide to standard inpatient care. Individual practice groups will serve as "clusters" and the unit of randomization. Each participating cluster will implement either the early discharge strategy using the intervention or standard care for initial two-month blocks, followed by a crossover to the alternate strategy. The primary outcome is days alive and out of hospital at 30 days.Read full original descriptionShow less
Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure: A Cluster-Randomized Crossover Non-Inferiority Trial
This will be a prospective, cluster-randomized, crossover, non-inferiority trial of 250 participants within 48 hours of an inpatient admission for heart failure or emergency department presentation for heart failure with plans for admission or observation/short-stay hospitalization comparing early discharge using subcutaneous furosemide to standard inpatient care. Individual practice groups will serve as "clusters" and the unit of randomization. Each participating cluster will implement either the early discharge strategy using the intervention or standard care for initial two-month blocks, followed by a crossover to the alternate strategy. The primary outcome is days alive and out of hospital at 30 days.
Inclusion: Age ≥ 18 years; Within 48 hours of inpatient stay OR ED presentation for HF with plans for admission OR observation stay/short-stay hospitalization for HF; Expected to require at least 24 additional hours of IV diuretics; Adequate home environment for self-care; Patient or caregiver capable of operating subcutaneous delivery device.
Exclusion: Cognitive impairment preventing informed consent; Type 1 myocardial infarction during index admission; End-stage HF with receipt or consideration of heart transplant or LVAD or requiring inotropic or mechanical circulatory support; eGFR <20 mL/min/1.73m2; Potassium <3.0 or >6.0 mmol/L or sodium <125 mmol/L; Geographic barriers to follow-up; Pregnancy or breastfeeding; IV furosemide requirement >250mg/day.